These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 34011083)

  • 21. ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.
    Pietrantonio F; Di Nicolantonio F; Schrock AB; Lee J; Tejpar S; Sartore-Bianchi A; Hechtman JF; Christiansen J; Novara L; Tebbutt N; Fucà G; Antoniotti C; Kim ST; Murphy D; Berenato R; Morano F; Sun J; Min B; Stephens PJ; Chen M; Lazzari L; Miller VA; Shoemaker R; Amatu A; Milione M; Ross JS; Siena S; Bardelli A; Ali SM; Falcone A; de Braud F; Cremolini C
    J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29370427
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement.
    Antonescu CR; Suurmeijer AJ; Zhang L; Sung YS; Jungbluth AA; Travis WD; Al-Ahmadie H; Fletcher CD; Alaggio R
    Am J Surg Pathol; 2015 Jul; 39(7):957-67. PubMed ID: 25723109
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular Characterization of Inflammatory Tumors Facilitates Initiation of Effective Therapy.
    Wachter F; Al-Ibraheemi A; Trissal MC; Hollowell M; DuBois SG; Collins NB; Church AJ; Janeway KA
    Pediatrics; 2021 Dec; 148(6):. PubMed ID: 34814185
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Case report: Crizotinib is effective in a patient with ROS1-rearranged pulmonary inflammatory myofibroblastic tumor.
    Mai S; Xiong G; Diao D; Wang W; Zhou Y; Cai R
    Lung Cancer; 2019 Feb; 128():101-104. PubMed ID: 30642440
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outstanding Response in a Patient With ROS1-Rearranged Inflammatory Myofibroblastic Tumor of Soft Tissues Treated With Crizotinib: Case Report.
    Comandini D; Catalano F; Grassi M; Pesola G; Bertulli R; Guadagno A; Spina B; Mascherini M; De Cian F; Pistoia F; Rebuzzi SE
    Front Oncol; 2021; 11():658327. PubMed ID: 34211840
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chromoplectic TPM3-ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib.
    Mansfield AS; Murphy SJ; Harris FR; Robinson SI; Marks RS; Johnson SH; Smadbeck JB; Halling GC; Yi ES; Wigle D; Vasmatzis G; Jen J
    Ann Oncol; 2016 Nov; 27(11):2111-2117. PubMed ID: 27742657
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Locally Advanced Inflammatory Myofibroblastic Tumor Treated With Targeted Therapy: A Case Report and Literature Review.
    Durham C; Clemons M; Alias A; Konduri K
    Cureus; 2022 Jul; 14(7):e27223. PubMed ID: 36035049
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel TPD52L2-ROS1 gene fusion expanding the molecular alterations in inflammatory myofibroblastic tumor: case report and literature review.
    Liu X; Duan Y; Wang G; Zhu P
    Diagn Pathol; 2023 Sep; 18(1):105. PubMed ID: 37735390
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Uterine Inflammatory Myofibroblastic Neoplasms With Aggressive Behavior, Including an Epithelioid Inflammatory Myofibroblastic Sarcoma: A Clinicopathologic Study of 9 Cases.
    Collins K; Ramalingam P; Euscher ED; Reques Llanos A; García A; Malpica A
    Am J Surg Pathol; 2022 Jan; 46(1):105-117. PubMed ID: 34138797
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inflammatory Myofibroblastic Tumor of the Lung: Two Progressing Pulmonary Nodules in a 25-Year-Old Adult With a Moraxella catharalis Infection.
    Schweckendiek D; Inci I; Schneiter D; Weder W
    Ann Thorac Surg; 2015 Dec; 100(6):e123-4. PubMed ID: 26652567
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Crizotinib in ALK
    Theilen TM; Soerensen J; Bochennek K; Becker M; Schwabe D; Rolle U; Klingebiel T; Lehrnbecher T
    Pediatr Blood Cancer; 2018 Apr; 65(4):. PubMed ID: 29286567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel ALK rearrangement in an inflammatory myofibroblastic tumor in a neonate.
    Owusu-Brackett N; Johnson R; Schindel DT; Koduru P; Cope-Yokoyama S
    Cancer Genet; 2013; 206(9-10):353-6. PubMed ID: 24290361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial.
    Schöffski P; Sufliarsky J; Gelderblom H; Blay JY; Strauss SJ; Stacchiotti S; Rutkowski P; Lindner LH; Leahy MG; Italiano A; Isambert N; Debiec-Rychter M; Sciot R; Van Cann T; Marréaud S; Nzokirantevye A; Collette S; Wozniak A
    Lancet Respir Med; 2018 Jun; 6(6):431-441. PubMed ID: 29669701
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pulmonary inflammatory myofibroblastic tumor after Hodgkin's lymphoma and application of PET imaging.
    Howman-Giles R; London K; McCowage G; Graf N; Harvey J
    Pediatr Surg Int; 2008 Aug; 24(8):947-51. PubMed ID: 18528695
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neoadjuvant crizotinib in ALK-rearranged inflammatory myofibroblastic tumor of the urinary bladder: A case report.
    Nagumo Y; Maejima A; Toyoshima Y; Komiyama M; Yonemori K; Yoshida A; Fujimoto H
    Int J Surg Case Rep; 2018; 48():1-4. PubMed ID: 29758320
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sustained complete response on crizotinib in primary lung inflammatory myofibroblastic tumor - Case report and literature review.
    Mittal A; Gupta A; Dhamija E; Barwad A; Rastogi S
    Monaldi Arch Chest Dis; 2021 Mar; 91(3):. PubMed ID: 33794589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neoadjuvant crizotinib in advanced inflammatory myofibroblastic tumour with ALK gene rearrangement.
    Rafee S; Elamin YY; Joyce E; Toner M; Flavin R; McDermott R; Sheehy N; Hennessy B; O'Byrne K; Gleeson N; Osman N
    Tumori; 2015 Apr; 101(2):e35-9. PubMed ID: 25744866
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration.
    Pearson ADJ; Barry E; Mossé YP; Ligas F; Bird N; de Rojas T; Zimmerman ZF; Wilner K; Woessmann W; Weiner S; Weigel B; Venkatramani R; Valteau D; Trahair T; Smith M; Singh S; Selvaggi G; Scobie N; Schleiermacher G; Richardson N; Park J; Nysom K; Norga K; Merino M; McDonough J; Matloub Y; Marshall LV; Lowe E; Lesa G; Irwin M; Karres D; Gajjar A; Doz F; Fox E; DuBois SG; Donoghue M; Casanova M; Caron H; Buenger V; Bradford D; Blanc P; Barone A; Reaman G; Vassal G
    Eur J Cancer; 2021 Nov; 157():198-213. PubMed ID: 34536944
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ALK-negative urachal inflammatory myofibroblastic tumor in an elderly female: A case report.
    Wang K; Zhou H; Lu Y; Lu Q; Zhang C; Zhou X; Xia S; Wang G
    Medicine (Baltimore); 2018 Dec; 97(51):e13619. PubMed ID: 30572472
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ALK inhibition in two emblematic cases of pediatric inflammatory myofibroblastic tumor: Efficacy and side effects.
    Brivio E; Zwaan CM
    Pediatr Blood Cancer; 2019 May; 66(5):e27645. PubMed ID: 30697903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.